Regeneron Pharmaceuticals, Inc.
Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments

Last updated:

Abstract:

The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).

Status:
Grant
Type:

Utility

Filling date:

15 Sep 2020

Issue date:

23 Mar 2021